search tick cross clock tag video marker play chevron-left chevron-right plus calendar chevron-up chevron-down external-link phone twitter facebook rss google-plus caret envelope linkedin angle-left angle-right circle-o circle info info warning youtube-play archive hamburger


Find out how we can help you

Contact Us Today

Healthcare Brochure

Mailing List

Receive CPI's latest news delivered to your inbox.

Sign up to our Mailing List


  • Formulation
  • The future of biopharma manufacturing


Traditional methods of pharmaceuticals manufacturing are evolving. There is a growing need to reduce production costs, and technology is required to facilitate the industry wide shift towards personalised medicines which demand a flexible production line capable of quickly switching between small lots of a wide range of drugs. There are great opportunities open to those innovators able to develop the novel pharmaceutical solutions to meet these challenges.

CPI provides industry and academia with a more cost effective, lower risk route into researching and scaling-up advanced pharmaceutical formulations. We offer world class open access facilities and the technical expertise required to help our partners develop new formulations in areas such as solid dosage, parenteral, inhalation and suspension formulation and encapsulations for release profiling.


The Future of Biopharmaceutical Manufacturing

The traditional model of large scale batch manufacturing facilities with high capital costs and highly purified services requirements has served the industry well to date, but if a reformed, personalised approach to pharmaceuticals is to be achieved, a radical redesign of processes and facilities will be required.

In the future, patient diagnostics will categorise an individual’s disease and determine the most effective therapeutic from a range of treatments based on their biological characteristics. Drugs will be manufactured according to demand, using a small-scale, on-site manufacturing unit, that can be rapidly reconfigured for different medicines.

What might the factory of the future look like?

CPI is working towards making small format upstream to downstream production a reality by helping companies to scale down traditional biopharmaceutical manufacturing.

The process technologies necessary to manufacture a product could be miniaturised and intensified into self-contained, flexibly-deployed manufacturing units whilst maintaining current clean room standards. Operation of these units would mainly rely on automation, with very little human intervention.

One of the key attributes of these future purification processes will be the ability to provide real time measurement and control, to enable the real time release of products. This is perhaps the greatest development challenge to overcome for this vision to become a reality.

The ultimate goal is to provide patients with access to effective, precision medicines whenever and wherever required, whilst using sustainable and cost effective methods.